Vaxcyte Reports Strong Cash Position and Significant Clinical Progress for VAX-31 Programs
PCVX has more than doubled off its 52-week low of $27.66.
Summary
Vaxcyte reported its Q4 and full-year 2025 financial results, showcasing a strong cash position of approximately $3 billion (including recent equity offering proceeds) and significant advancements in its VAX-31 adult and infant vaccine programs.
Key Events · Earnings and Guidance · PCVX
-
Strong Cash Position
Reported approximately $2.4 billion in cash, cash equivalents, and investments as of December 31, 2025, further strengthened by $600.2 million in net proceeds from a February 2026 equity offering, providing a substantial cash runway.
-
VAX-31 Adult Phase 3 Program Advances
Initiated a comprehensive VAX-31 adult Phase 3 clinical program with three studies (OPUS-1, OPUS-2, OPUS-3) underway, finalized in consultation with the FDA, to support a planned Biologics License Application (BLA) submission. Topline data for OPUS-1 is expected in Q4 2026, and for OPUS-2 and OPUS-3 in H1 2027.
-
VAX-31 Infant Phase 2 Enrollment Completed
Completed enrollment in the VAX-31 infant Phase 2 dose-finding study, with topline safety, tolerability, and immunogenicity data expected by the end of H1 2027.
-
Pipeline Expansion and Manufacturing Progress
Plans to initiate a Phase 1 adult clinical study for VAX-A1 (Group A Strep vaccine) in 2026. Completed construction of a dedicated manufacturing facility with Lonza and initiated buildout of a North Carolina fill-finish line to support future commercialization.
Analysis · PCVX · Life Sciences
Vaxcyte's latest earnings report highlights substantial progress across its vaccine pipeline and a robust financial position. The initiation of three Phase 3 clinical trials for VAX-31 in adults, along with the completion of enrollment for the infant Phase 2 study, demonstrates strong execution on key development milestones. The company's cash reserves, significantly bolstered by a recent $600.2 million net equity offering, provide a long runway to fund these extensive clinical programs and manufacturing buildouts. While R&D expenses and net loss increased, this is expected for a clinical-stage biotech advancing multiple late-stage assets. The strategic appointments to the leadership team and board further support the company's trajectory towards potential commercialization.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 35.6% of the 1805 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PCVX was trading at $61.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.7B. The 52-week trading range was $27.66 to $83.33. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.